ROIV
Roivant Sciences Ltd.
$14.81
-$0.13(-0.90%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$9.68B
Volume
5.61M
52W Range
$8.73 - $16.05
Target Price
$20.05
Order:
Income Statement
| Metric | Trend | Chart | 2022 Mar | 2023 Mar | 2024 Mar | 2025 Mar |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $55.3M | $61.3M | $32.7M | $29.1M | ||
| Total Revenue | $55.3M | $61.3M | $32.7M | $29.1M | ||
| COST OF GOODS SOLD | ||||||
| Cost of Revenue | $9.0M | $13.1M | $15.6M | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $46.3M | $48.2M | $32.7M | $29.1M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $1.4B | $1.2B | $884.1M | $1.1B | ||
| Research & Development | $483.0M | $525.2M | $439.9M | $550.4M | ||
| Research Expense | $483.0M | $525.2M | $439.9M | $550.4M | ||
| Selling, General & Administrative | $775.0M | $600.5M | $416.1M | $591.4M | ||
| General & Administrative Expenses | $775.0M | $600.5M | $416.1M | $591.4M | ||
| Salaries & Wages | $-565.0M | -- | -- | -- | ||
| Amortization | -- | $144.9M | $137.8M | -- | ||
| Other Operating Expenses | $148.9M | -- | -- | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-1.4B | $-1.2B | $4.5B | $-1.0B | ||
| EBITDA | $-910.8M | $-1.2B | $4.6B | $-660.7M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $7.0M | $28.0M | $34.8M | -- | ||
| Interest Income Operating | $369.0K | -- | -- | -- | ||
| Intinc | $369.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $6.7M | $-4.2M | $-34.8M | -- | ||
| Gain on Sale of Securities | $361.5M | $-20.8M | $-48.0M | $55.2M | ||
| Other Income/Expense | $294.7M | $-151.5M | $28.8M | $-47.6M | ||
| Other Special Charges | $69.7M | $15.8M | $-13.6M | $-10.7M | ||
| SPECIAL ITEMS | ||||||
| Special Income Charges | $3.4M | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-916.7M | $-1.2B | $4.6B | $-681.6M | ||
| Pre-Tax Income | $-923.7M | $-1.2B | $4.6B | $-681.6M | ||
| INCOME TAX | ||||||
| Tax Provision | $369.0K | $5.2M | $21.5M | $48.2M | ||
| NET INCOME | ||||||
| Net Income | $-845.3M | $-1.0B | $4.3B | $-172.0M | ||
| Net Income (Continuing Operations) | $-924.1M | $-1.2B | $4.5B | $-729.8M | ||
| Net Income (Discontinued Operations) | $-845.3M | $-1.0B | $4.3B | $-172.0M | ||
| Net Income (Common Stockholders) | $-845.3M | $-1.0B | $4.3B | $-172.0M | ||
| Normalized Income | -- | -- | -- | $-677.9M | ||
| TOTALS | ||||||
| Total Expenses | $1.3B | $1.2B | $884.1M | $1.1B | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $669.8M | $712.8M | $783.2M | $725.4M | ||
| Average Shares Outstanding (Diluted) | $669.8M | $712.8M | $831.0M | $725.4M | ||
| Shares Outstanding | $700.8M | $766.8M | $738.7M | $679.8M | ||
| Basic EPS | $-1.26 | $-2.84 | $5.55 | $-0.48 | ||
| Basic EPS (Continuing Operations) | $-1.26 | $-3 | $11.1 | $-0.99 | ||
| Diluted EPS | $-1.26 | $-2.84 | $5.23 | $-0.48 | ||
| Diluted EPS (Continuing Operations) | -- | $-3 | $10.46 | $-0.99 | ||
| OTHER METRICS | ||||||
| Acquired In Process Rn D | $3.4M | -- | -- | -- | ||
| Acquired In Process Rn D Income | $5.0M | -- | -- | -- | ||
| Basic Discontinuous Operations | -- | $0.16 | -- | $0.51 | ||
| Diluted Discontinuous Operations | -- | $0.16 | -- | $0.51 | ||
| Gain On Sale Of Business | $69.8M | $29.3M | $32.8M | $3.1M | ||
| Minority Interests | $78.9M | $106.4M | $117.7M | $184.8M | ||
| Net Income Discontinuous Operations | -- | $114.6M | $-315.1M | $373.0M | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | $114.6M | $-315.1M | $373.0M | ||
| Other Gand A | $775.0M | $600.5M | $416.1M | $591.4M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ROIV | $14.81 | -0.9% | 5.61M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |